Palo Alto, California, 3 August 2010 – OroScience plc (Palo Alto, CA) announces successful completion of its 3 year ISO13485 CMDCAS re-certification audit. “The successful completion of this intensive 2 day audit is an important operational milestone and provides independent confirmation of OroScience’s commitment and capability to repeatedly and reliably produce high quality medical products,” said Phil Houle, Chief Operating Officer. “It is also a critical element in allowing OroScience to expand the distribution of our wound care emulsion into the Canadian and European markets, planned for the fourth quarter of this year,” commented Mark G. Fontenot, ME, MBA,DDS, Chief Executive Officer of OroScience. Dr. Fontenot added that, “the introduction of our oral wound care emulsion, Curative, into the European market represents a significant financial opportunity for OroScience. We estimate the Canadian and European market opportunity for Curative to be on the order of €250M annually and are actively working to develop distribution capabilities there.”
About OroScience
OroScience is a global professional oral care company dedicated to providing advanced therapies for the professional management of oral conditions such as oral wounds and mucositis. Our mission, helping nature heal, is woven into the fabric of OroScience’s organization and vision. In collaboration with leading clinicians, we develop, manufacture, and sell proprietary therapeutic dental and oral care products for oral wound healing, tissue regeneration, and oral disease management.
** END OF PRESS RELEASE **
OroScience plc is an independent, stock exchange listed manufacturer of professional oral care products. This news release may contain certain forward-looking statements, expectations, intentions, strategies and beliefs regarding the future. All statements contained herein are based upon information available to the management of OroScience plc as of the date hereof, and actual results may vary based upon future events, both within and without the control of the management, including risks and uncertainties that could cause actual results to differ materially.
Management does not take any responsibility to update the contents of this News Release in case new aspects arise or new conditions change the facts available.
OroScience, plc
2275 E. Bayshore Rd., Suite 105
Palo Alto, CA 94301 USA
www.oroscience.com
ISIN IE00B40WCY19, WKN A0X9H7,
Exchange: Vienna stock exchange, Frankfurt Stock Exchange
Media Contact: OroScience
Phil Houle
Chief Operations Officer
phoule@oroscience.com
